
Kunal Potnis, MD
93 posts

Kunal Potnis, MD
@KunalPotnis
Incoming fellow @FredHutch/@UW | PGY-3 @YaleIMed | @YaleMed '23, @DukeU '17 | Interested in intersection of hematology/oncology, economics, & policy




Kunal Potnis, MD, discusses an analysis of the cost-effectiveness of #ribociclib plus endocrine therapy compared to endocrine therapy alone among patients with HR-positive, HER2-negative early breast cancer. Learn more: hubs.ly/Q03sjl9x0 #medtwitter #onctwitter











CRISPR therapies can treat disease but cost millions. An equity-based approach could bring them to more people. Read the new article from @KunalPotnis and @GeorgeGoshuaMD: thebulletin.org/2024/10/crispr…





Congratulations to the newly matched residents in our Internal Medicine Traditional Residency Program! Welcome to @YaleMed @Yale @YNHH! 🧵 #MatchDay2024 #Residency #MedTwitter #Match2024 @MarkDSiegel1 @TradIMYale













